Aurobindo Pharma Transfers Generic Formulations to Auropharm

Aurobindo Pharma has approved the generic formulations transfer of its domestic branded generic formulations products business to its wholly owned subsidiary, Auropharm.

Announced today, the move is part of a strategic restructuring to sharpen focus on its India operations.

This Aurobindo Pharma generic formulations transfer will be executed through a Business Transfer Agreement on a going concern basis, ensuring continuity of assets, employees, and operations.

The company said the decision is aimed at simplifying its structure and improving operational efficiency. By moving its domestic formulations products business under Auropharm, Aurobindo Pharma is creating a more focused vertical for the Indian market while freeing up the parent entity to concentrate on global business segments.

Also Read: The Future of MedTech in India: Meeting Tier-2 and Tier-3 Needs

This restructuring supports the company’s long-term strategy to strengthen its position in the branded generics India market. The Aurobindo Pharma generic formulations transfer is expected to reduce complexity and enable faster decision-making within its domestic pharma business.

Auropharm, which already handles India-focused operations, will now manage a more integrated portfolio, helping drive growth and execution in a competitive landscape. The transition is structured to be seamless, with no disruption to existing business operations.

Aurobindo Pharma clarified that this is an internal realignment and does not impact ownership. Instead, it reflects a targeted effort to build a streamlined and scalable business structure for sustained growth.